🇪🇺 Telzir® in European Union

EMA authorised Telzir® on 12 July 2004

Marketing authorisation

EMA — authorised 12 July 2004

  • Application: EMEA/H/C/000534
  • Marketing authorisation holder: ViiV Healthcare BV
  • Local brand name: Telzir
  • Indication: Telzir in combination with low-dose ritonavir is indicated for the treatment of human-immunodeficiency-virus-type-1-infected adults, adolescents and children of six years and above in combination with other antiretroviral medicinal products. In moderately antiretroviral-experienced adults, Telzir in combination with low-dose ritonavir has not been shown to be as effective as lopinavir / ritonavir. No comparative studies have been undertaken in children or adolescents. In heavily pretreated patients, the use of Telzir in combination with low-dose ritonavir has not been sufficiently studied. In
  • Status: withdrawn

Read official source →

Other Infectious Disease approved in European Union

Frequently asked questions

Is Telzir® approved in European Union?

Yes. EMA authorised it on 12 July 2004.

Who is the marketing authorisation holder for Telzir® in European Union?

ViiV Healthcare BV holds the EU marketing authorisation.